Nanoencapsulation of leech saliva extract proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
Research article published in BioImpacts (2021)
Abstract
Introduction: Breast cancer is the most serious cause of women's death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes' hydrophilic core is essential to develop a therapeutic protein carrier system. We aimed to encapsulate the medicinal leech saliva extract (LSE) and assess the inhibition of angiogenesis of breast cancer cells by targeting vascular endothelial growth factor A (VEGFA). Methods: In this research, enhanced formulation of liposomal protein was determined by zeta potential analysis, droplet size, drug release assay, and transmission electron microscopy (TEM). Furthermore, a cytotoxicity assay of liposomal LSE was performed to determine the cytotoxic activity of components. For assessing the expression of VEGFA, P53, and hypoxia-inducible factor subunit alpha (HIF1a) genes, Real-Time PCR was applied. Results: Nano liposome was chosen as an enhanced formulation due to its much smaller size (46.23 nm). Liposomal LSE had more practical actions on the MCF-7 cells. As noticed by DAPI staining, apoptosis was extensively greater in treated MCF-7 cells. Wound healing assay demonstrated that MCF-7 cells could not sustain growth at the presence of liposomal LSE and expression of the VEGFA gene was declined in treated cells. Downregulation of VEGFA was evaluated with western blotting technique. Conclusion: It can be concluded that our investigation of the tests confirmed the fact that nano liposomal LSE is a novel promising formulation for anticancer drugs and can significantly improve the penetration of protein drugs to cancer cells.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Nanoencapsulation of leech saliva extract proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7).
Warum dies für die Hirudotherapie relevant ist
Diese In-vitro-Studie untersuchte, ob ein Extrakt aus dem Speichel medizinischer Blutegel (LSE), verkapselt in Liposomen (~46,23 nm), die Angiogenese in MCF-7-Brustkrebszellen hemmen kann, wobei Zytotoxizität, Apoptose mittels DAPI-Färbung, Wundheilung und VEGFA-Expression mittels Real-Time-PCR und Western Blot untersucht wurden. Für die ASH und die Hirudotherapie ist diese Arbeit unmittelbar relevant: Sie untersucht die Bioaktivität des Blutegel-Sekretoms und zeigt eine Nanocarrier-Strategie auf, welche die Verabreichung und Stabilität blutegelstämmiger Proteine für therapeutische Anwendungen verbessern könnte. Die Ergebnisse zeigten, dass liposomales LSE im Vergleich zu Kontrollen die Apoptose steigerte, das Zellwachstum in Wundheilungsassays beeinträchtigte und VEGFA in behandelten Zellen herunterregulierte. Diese Befunde sind jedoch auf eine einzelne Krebszelllinie in vitro beschränkt und stellen keinen Nachweis einer klinischen antitumoralen Wirksamkeit dar; weitere In-vivo- und klinische Studien sind erforderlich, bevor therapeutische Aussagen gemacht werden können.
Zitation
Nanoencapsulation of leech saliva extract proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
Shakouri A et al. · BioImpacts, 2021
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026